ArticleThe Korean journal of parasitology2022
Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.
Article in The Korean journal of parasitology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 64 citations in OpenAlex.
- High-Throughput Screening Identifies Novel Antileishmanial Scaffolds and Reveals Cross-Species Activity of Structurally Diverse Compounds.Research square · 2026Article
- Immunoinformatics-Driven Identification of Conserved Multi-Epitope Vaccine Candidates from PDI Protein of Leishmania Donovani for Visceral Leishmaniasis.Cell biochemistry and biophysics · 2026Article
- Bulky pcDNA plasmid encoding Leishmania- and Sandfly-derived antigens resulted in transient Th1 response post Leishmania major infection in BALB/c mice.Scientific reports · 2026Article
- A Human Monoclonal Antibody Targeting α-Gal Ameliorates Experimental Cutaneous Leishmaniasis.The Journal of infectious diseases · 2026Article
- Leishmaniasis vaccine research: current status and new directions.Parasitology · 2026Review
- Pathogenic Significance of Trypanosomatids: Progress in Drug Resistance, Control Strategies, and Artificial Intelligence.Interdisciplinary perspectives on infectious diseases · 2026Review
- Attitudes and acceptance of vaccination against neglected tropical diseases: A multi-country study in Asia.Human vaccines & immunotherapeutics · 2025Article
- Attitudes and acceptance of mRNA-based vaccine for neglected tropical diseases: A multi-country study in Asia.Human vaccines & immunotherapeutics · 2025Article
- CRISPR-Cas13b mediated gene knockdowns in Leishmania infantum.International journal for parasitology. Drugs and drug resistance · 2025Article
- Repurposing Acetylcholinesterase Inhibitors for Leishmaniasis: Donepezil Hydrochloride and Related Compounds Against the American Tegumentary Form.Antibiotics (Basel, Switzerland) · 2025Article
- Genetic Manipulation Tools in Leishmania: From CRISPR/Cas9 to Vaccine Strategies for Disease Control.Acta parasitologica · 2025Review
- Intracellular Parasitic Infections Caused byVaccines · 2025Review
- Article
- Cutaneous Leishmaniasis in the Context of Global Travel, Migration, Refugee Populations, and Humanitarian Crises.Clinics and practice · 2025Review
- Vaccines in Dermatology-Present and Future: A Review.Vaccines · 2025Review
- Understanding Sex-biases in Kinetoplastid Infections: Leishmaniasis and Trypanosomiasis.Expert reviews in molecular medicine · 2025Review
- Human migrations, anthropogenic changes, and insect-borne diseases in Latin America.Parasites & vectors · 2025Review
- In silico design and assessment of a multiepitope and multiantigen potential vaccine candidate againstIn silico pharmacology · 2025Article
- Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication.Current drug discovery technologies · 2025Review
- Assessment of Autophagy in Leishmania Parasites.Methods in molecular biology (Clifton, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is a serious parasitic disease caused by Leishmania spp. transmitted through sandfly bites. This disease is a major public health concern worldwide. It can occur in 3 different clinical forms: cutaneous, mucocutaneous, and visceral Leishmaniasis (CL, MCL, and VL, respectively), caused by different Leishmania spp. Currently, licensed vaccines are unavailable for the treatment of human Leishmaniasis. The treatment and prevention of this disease rely mainly on chemotherapeutics, which are highly toxic and have an increasing resistance problem. The development of a safe, effective, and affordable vaccine for all forms of vector-borne disease is urgently needed to block transmission of the parasite between the host and vector. Immunological mechanisms in the pathogenesis of Leishmaniasis are complex. IL-12-driven Th1-type immune response plays a crucial role in host protection. The essential purpose of vaccination is to establish a protective immune response. To date, numerous vaccine studies have been conducted using live/attenuated/killed parasites, fractionated parasites, subunits, recombinant or DNA technology, delivery systems, and chimeric peptides. Most of these studies were limited to animals. In addition, standardization has not been achieved in these studies due to the differences in the virulence dynamics of the Leishmania spp. and the feasibility of the adjuvants. More studies are needed to develop a safe and effective vaccine, which is the most promising approach against Leishmania infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.